Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nisha Ghatwai"'
Autor:
Afshan F. Nawas, Mohammed Kanchwala, Shayna E. Thomas-Jardin, Haley Dahl, Kelly Daescu, Monica Bautista, Vanessa Anunobi, Ally Wong, Rachel Meade, Ragini Mistry, Nisha Ghatwai, Felix Bayerl, Chao Xing, Nikki A. Delk
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatm
Externí odkaz:
https://doaj.org/article/88805b75fcd54574962ff2f13e8e4534
Autor:
Andras Heczey, Xin Xu, Amy N. Courtney, Gengwen Tian, Gabriel A. Barragan, Linjie Guo, Claudia Martinez Amador, Nisha Ghatwai, Purva Rathi, Michael S. Wood, Yanchuan Li, Chunchao Zhang, Thorsten Demberg, Erica J. Di Pierro, Andrew C. Sher, Huimin Zhang, Birju Mehta, Sachin G. Thakkar, Bambi Grilley, Tao Wang, Brian D. Weiss, Antonino Montalbano, Meena Subramaniam, Chenling Xu, Chirag Sachar, Daniel K. Wells, Gianpietro Dotti, Leonid S. Metelitsa
Publikováno v:
Nature Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b13a82f4a138ed6484a1cd3ee3f4400
https://doi.org/10.1038/s41591-023-02363-y
https://doi.org/10.1038/s41591-023-02363-y
Autor:
Vanessa Anunobi, Monica Bautista, Kelly Daescu, Nikki A. Delk, Rachel Meade, Haley Dahl, Chao Xing, Felix Bayerl, Ally Wong, Nisha Ghatwai, Ragini Mistry, Mohammed Kanchwala, Afshan Fathima Nawas, Shayna E. Thomas-Jardin
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Background Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0fb4155b741e2383ec7aa849c6998f3
https://doaj.org/article/88805b75fcd54574962ff2f13e8e4534
https://doaj.org/article/88805b75fcd54574962ff2f13e8e4534
Autor:
Afshan F, Nawas, Mohammed, Kanchwala, Shayna E, Thomas-Jardin, Haley, Dahl, Kelly, Daescu, Monica, Bautista, Vanessa, Anunobi, Ally, Wong, Rachel, Meade, Ragini, Mistry, Nisha, Ghatwai, Felix, Bayerl, Chao, Xing, Nikki A, Delk
Publikováno v:
BMC Cancer
Background Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::69a5ea66f1d2d5d9ab46393b6df7f1fe
https://pubmed.ncbi.nlm.nih.gov/31959131
https://pubmed.ncbi.nlm.nih.gov/31959131
Autor:
Nisha Ghatwai, Brijesh Arora, Asma Bibi, Nikesh Kunder, Nikhil Patkar, Papagudi Ganesan Subramanian, Prathibha Amare, Prashant Tembhare, Gaurav Narula, Shripad Banawali, Nilesh Deshpande, Y. Badrinath, Gaurav Chatterjee, Sumeet Gujral, Sitaram Ghogale
Publikováno v:
Cytometry Part B: Clinical Cytometry. 94:100-111
Background Multiparametric flow cytometry (MFC) is a popular technique for minimal residual disease (MRD) analysis. However, its applicability is still limited to 90% of B-cell precursor acute lymphoblastic leukemia (BCPALL) due to two major issues,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::658ff22a41648fa4ecef38469af5f349
https://doi.org/10.1002/cyto.b.21486
https://doi.org/10.1002/cyto.b.21486
Autor:
Prashant R, Tembhare, Sitaram, Ghogale, Nisha, Ghatwai, Yajamanam, Badrinath, Nikesh, Kunder, Nikhil V, Patkar, Asma R, Bibi, Gaurav, Chatterjee, Brijesh, Arora, Gaurav, Narula, Shripad, Banawali, Nilesh, Deshpande, Prathibha, Amare, Sumeet, Gujral, Papagudi G, Subramanian
Publikováno v:
Cytometry. Part B, Clinical cytometry. 94(1)
Multiparametric flow cytometry (MFC) is a popular technique for minimal residual disease (MRD) analysis. However, its applicability is still limited to 90% of B-cell precursor acute lymphoblastic leukemia (BCPALL) due to two major issues, i.e. a prop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::56d2614aa26f983f2ffe28bc417f6750
https://pubmed.ncbi.nlm.nih.gov/27718302
https://pubmed.ncbi.nlm.nih.gov/27718302